RecruitingFocal EpilepsyEpilepsyRefractory Focal Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Eligible age
18–70 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Sponsor: Rapport Therapeutics Inc.
You may qualify if…
- ✓ Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.
- ✓ Diagnosis of refractory focal epilepsy
- ✓ Stable RNS(c) system settings
- ✓ A demonstrated history of compliance with RNS(c) system data interrogation and upload
- ✓ Good overall health other than focal epilepsy, per Investigator.
- ✓ BMI ≥ 18 kg/m\^2 and ≤ 45 kg/m\^2
- ✓ Willing and able to adhere to all aspects of the protocol.
You may not qualify if…
- ✕ Known of hypersensitivity to RAP-219
- ✕ Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator
- ✕ Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods
Where it's recruiting
Source: ClinicalTrials.gov · NCT07219407 · last updated 2026-01-23